Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Issues
2013 Issues
March Vol 6 No 2
TON - March 2013, Vol 6, No 2
View Digital Edition
Predicting Risk of Significant Side Effects With OnPART
By
Alice Goodman
Supportive Care
TON - March 2013, Vol 6, No 2
— March 26, 2013
OnPART can predict 6 common side effects of dose-dense doxorubicin plus cyclophosphamide plus paclitaxel chemotherapy in patients with breast cancer with a high degree of accuracy, according to the results of a study presented at the CTRC-AACR San Antonio Breast Cancer Symposium.
Read More ›
Venlafaxine Lowers Endoxifen Levels, May Affect Tamoxifen Effectiveness
By
Caroline Helwick
Breast Cancer
TON - March 2013, Vol 6, No 2
— March 26, 2013
The antidepressant venlafaxine is often prescribed to patients with breast cancer who are taking tamoxifen, to help reduce the side effect of hot flashes. But according to research presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, venlafaxine may reduce the effectiveness of the drug.
Read More ›
IWTI 2013
Lynch Syndrome: An Interview With the Father of Hereditary Cancer Detection and Prevention, Henry T. Lynch, MD
Interview with the Innovators
TON - March 2013, Vol 6, No 2
— March 26, 2013
Lynch syndrome is a hereditary disorder caused by a mutation in a mismatch repair gene in which affected individuals have an increased risk of developing colorectal cancer, endometrial cancer, and various other types of aggressive cancers.
Read More ›
Introducing the Third Annual Conference of the Association for Value-Based Cancer Care
By
Burt Zweigenhaft, PhD, DLitt
Conference Correspondent
TON - March 2013, Vol 6, No 2
— March 26, 2013
As we know, the American healthcare system is going through exorbitant changes, changes that will affect all providers and all stakeholders in the cancer care ecosystem.
Read More ›
Peripheral Arterial Disease Seen With Nilotinib
By
Audrey Andrews
Supportive Care
TON - March 2013, Vol 6, No 2
— March 26, 2013
Peripheral artery occlusive disease (PAOD) may be an adverse effect of nilotinib treatment in patients with chronic-phase chronic myeloid leukemia (CML), according to a study presented at the 54th Annual Meeting of the American Society of Hematology.
Read More ›
Evidence Lacking for Eliminating Prophylactic Platelet Transfusions
By
Audrey Andrews
Supportive Care
TON - March 2013, Vol 6, No 2
— March 26, 2013
To prevent bleeding related to stem cell transplant or intense induction and conditioning regimens, prophylactic platelet infusion remains the standard of care, according to a study that compared outcomes for patients who received prophylaxis versus those who did not.
Read More ›
Home-Based TPN of Little Benefit in Terminally Ill Patients With GI Cancer
By
Audrey Andrews
;
Caroline Helwick
Supportive Care
,
Supportive Care
TON - March 2013, Vol 6, No 2
— March 26, 2013
Total parenteral nutrition (TPN) continues to be inappropriately used at the end of life in cancer patients, according to a review of home-based TPN reported by researchers from Moffitt Cancer Center in Tampa, Florida, at the 2013 Gastrointestinal Cancers Symposium.
Read More ›
Branded Versus Generic Enoxaparin: Biological Activity May Differ
By
Caroline Helwick
Conference Correspondent
TON - March 2013, Vol 6, No 2
— March 26, 2013
While branded and generic enoxaparin share many traditional characteristics of low-molecular-weight heparins (LMWHs), they differ in several parameters that are relevant to an antithrombotic effect, according to researchers from Loyola University Medical Center, Maywood, Illinois, who presented their findings at the 54th Annual Meeting of the American Society of Hematology.
Read More ›
Monitor Adverse Events Early With Regorafenib, Especially After Initiation
By
Wayne Kuznar
Supportive Care
TON - March 2013, Vol 6, No 2
— March 26, 2013
Adverse effects (AEs) with regorafenib tend to occur early—during the first treatment cycle—and then quickly taper off.
Read More ›
Abstracts of Interest From the 54th Annual Meeting of the American Society of Hematology
By
Caroline Helwick
Conference Correspondent
TON - March 2013, Vol 6, No 2
— March 26, 2013
At the ASH plenary session, investigators showed that acute promyelocytic leukemia (APL), traditionally one of the deadliest hematologic malignancies, can be treated without chemotherapy.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION